University of Antwerp

Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence

Retrieved on: 
Tuesday, February 27, 2024

The study fulfilled its primary aim of demonstrating safety and feasibility of Amber’s new surgical procedure, validating a scalable approach to accurately implant two electrode leads on the pudendal nerve.

Key Points: 
  • The study fulfilled its primary aim of demonstrating safety and feasibility of Amber’s new surgical procedure, validating a scalable approach to accurately implant two electrode leads on the pudendal nerve.
  • Clinically significant improvements in symptom-related quality-of-life were observed in both mixed and refractory urge UI patients.
  • In patients with mixed UI, this was manifest as reductions in both stress and urge incontinence events.
  • The study also demonstrated the utility of patient-controlled adaptive algorithms using Amber-UI’s integrated sensors.

Droplet-based Whole Genome Amplification: Successfully Sequencing Minute Amounts of Mycobacterium Tuberculosis DNA, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 28, 2024

TORONTO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Whole genome sequencing (WGS) is crucial for tuberculosis (TB) surveillance, but its implementation in patient care is hindered by the limited amount of Mycobacterium tuberculosis (Mtb) in clinical specimens and the slow growth of Mtb.

Key Points: 
  • In this free webinar, delve into the significance of whole genome sequencing (WGS) in advancing tuberculosis (TB) surveillance.
  • Attendees will learn how droplet-based multiple displacement amplification (dMDA) coupled with WGS helped successfully sequence minute amounts of Mtb DNA.
  • The control and 5 pg input dMDA samples underwent nanopore sequencing and were analysed using nanorate sequencing (Nanoseq) and TB-profiler.
  • Register for this webinar today to gain insights into how dMDA amplification coupled with whole genome sequencing helped successfully sequence minute amounts of Mtb DNA.

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Retrieved on: 
Thursday, December 7, 2023

Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.

Key Points: 
  • Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.
  • The in-person event will be held at the San Diego Marriott Gaslamp Quarter in the Presidio Ballroom B/C.
  • To register as an in-person attendee, please click here .
  • Galapagos leadership, including Paul Stoffels1, MD, CEO and Chairman, will provide updates on:
    A live question and answer will follow the formal presentations.

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Monday, September 25, 2023

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.
  • During her time at Agios, she has overseen early- and late-stage clinical development globally across multiple indications, including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
  • “I’ve dedicated much of my career to developing medicines for underserved patient populations across a range of therapeutic areas.
  • She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master’s in Medical Sciences from Harvard Medical School.

How to grow rhinos in a lab: the science that could save an endangered species

Retrieved on: 
Sunday, August 13, 2023

With the death of last male in 2018 and with only two females alive, the species is functionally extinct.

Key Points: 
  • With the death of last male in 2018 and with only two females alive, the species is functionally extinct.
  • In one of its research lines, the BioRescue team collects mature eggs – scientifically called oocytes – from one of the only two northern white females.
  • These eggs will be fertilised with frozen sperm that were collected from several northern white male rhinos before their death.
  • These techniques would not only save the northern white rhinoceros, but also other rhino species, related species with a common ancestor, and all other creatures in need.

Different approaches

    • Parallel initiatives focusing on different conservation approaches are indispensable to ensure the future of this species.
    • These supporting cells provide signals and components essential for the development of the eggs.
    • This would bypass atresia, which is the degradation of follicles that occurs during a natural hormonal cycle.
    • Due to a scarcity of tissues from endangered species, we are using the pig as a large animal model.
    • This will give us more in-depth knowledge on how to approach egg creation from stem cells already present in the animal, termed endogenous stem cells.

What next?

    • Researchers now know that samples of the northern white rhino individuals currently stored in biobanks have enough genetic variability to establish a viable and sustainable population.
    • This is becoming a reality that gives us hope, motivation and energy to save the northern white rhino.

Ivanti Names Seasoned Financial Executive Peter De Bock as Chief Financial Officer

Retrieved on: 
Monday, May 8, 2023

Ivanti , the technology company that elevates and secures Everywhere Work, has appointed software industry veteran Peter De Bock as the company’s Chief Financial Officer.

Key Points: 
  • Ivanti , the technology company that elevates and secures Everywhere Work, has appointed software industry veteran Peter De Bock as the company’s Chief Financial Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230508005257/en/
    Peter De Bock, Ivanti Chief Financial Officer (Photo: Business Wire)
    De Bock has more than 30 years of experience in the software industry both in large scale organizations and in high growth environments.
  • De Bock was most recently Chief Administrative Officer at Inovalon, provider of a cloud-based SaaS platform for the Healthcare industry.
  • As Ivanti continues to evolve our Neurons platform through organic and acquisition growth strategy, Peter will add tremendous value.”
    “Joining Ivanti at such an exciting time in the company’s growth trajectory is very attractive to me,” said Peter De Bock, Chief Financial Officer at Ivanti.

Materialise NV Announces New Chief Financial Officer

Retrieved on: 
Thursday, April 27, 2023

Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and sophisticated 3D printing services, today announced that Koen Berges has been named the company’s new chief financial officer effective May 15, 2023.

Key Points: 
  • Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and sophisticated 3D printing services, today announced that Koen Berges has been named the company’s new chief financial officer effective May 15, 2023.
  • Mr. Berges will succeed long-time CFO Johan Albrecht, who has decided to leave Materialise at the end of May to pursue new opportunities.
  • Fried Vancraen, founder and chief executive officer of Materialise, commented: “Johan has been instrumental in the growth of Materialise to where we are today as a publicly traded 3D printing group.
  • Mr. Vancraen noted, “Koen’s extensive business experience and financial acumen make him the ideal person to succeed Johan.

Hilco Performance Solutions Names Former Ford Motor Company Business Leader Frederic Vanlinthout Automotive Industry Practice Leader

Retrieved on: 
Tuesday, March 21, 2023

DETROIT, March 21, 2023 /PRNewswire/ -- Hilco Performance Solutions (HPS) , a management advisory firm that consists of operational and financial experts in the areas of Manufacturing, Supply Chain, Sales & Customer Experience, Organizational Design, and M&A has named Frederic Vanlinthout Automotive Industry Practice Leader.

Key Points: 
  • DETROIT, March 21, 2023 /PRNewswire/ -- Hilco Performance Solutions (HPS) , a management advisory firm that consists of operational and financial experts in the areas of Manufacturing, Supply Chain, Sales & Customer Experience, Organizational Design, and M&A has named Frederic Vanlinthout Automotive Industry Practice Leader.
  • An operating company of Hilco Global, HPS helps clients simplify and streamline business processes and improve operational efficiencies.
  • Prior to Ford he was a Senior Management Consultant at American International Group and a Global Business Development Manager at Société Générale de Surveillance.
  • Along with his Automotive Industry Lead position, Frederic will continue to support his manufacturing client base.

Hilco Performance Solutions Expands its Advisory Practice with the Addition of Two Associate Directors, Steve Savoy, and Frederic Vanlinthout

Retrieved on: 
Tuesday, March 7, 2023

In announcing the additions, Steven Tanzi, President of Hilco Performance Solutions said, "We are very excited to add these two outstanding individuals to HPS. They are the ideal combination of advisory experts and industry practitioners to be hands-on client partners. Steve is focused on operations and procurement and Frederic on finance and strategy.  Both-- together with our existing HPS team—will provide problem-solving, issue resolution, process improvement, help our clients execute more quickly and develop new skills in their organization, and improve financial results."

Key Points: 
  • An operating company of Hilco Global, HPS helps clients simplify and streamline business processes and improve operational efficiencies.
  • In announcing the additions, Steven Tanzi, President of Hilco Performance Solutions said, "We are very excited to add these two outstanding individuals to HPS.
  • They are the ideal combination of advisory experts and industry practitioners to be hands-on client partners.
  • Steve is focused on operations and procurement and Frederic on finance and strategy.

Hilco Performance Solutions Expands its Advisory Practice with the Addition of Two Associate Directors, Steve Savoy, and Frederic Vanlinthout

Retrieved on: 
Tuesday, February 7, 2023

In announcing the additions, Steven Tanzi, President of Hilco Performance Solutions said, "We are very excited to add these two outstanding individuals to HPS. They are the ideal combination of advisory experts and industry practitioners to be hands-on client partners. Steve is focused on operations and procurement and Frederic on finance and strategy.  Both-- together with our existing HPS team—will provide problem-solving, issue resolution, process improvement, help our clients execute more quickly and develop new skills in their organization, and improve financial results."

Key Points: 
  • An operating company of Hilco Global, HPS helps clients simplify and streamline business processes and improve operational efficiencies.
  • In announcing the additions, Steven Tanzi, President of Hilco Performance Solutions said, "We are very excited to add these two outstanding individuals to HPS.
  • They are the ideal combination of advisory experts and industry practitioners to be hands-on client partners.
  • Steve is focused on operations and procurement and Frederic on finance and strategy.